Empowering Mid-Size Pharma Companies With Integrated Drug Development, Regulatory Strategy, And AI Innovation

By Michelle Gyzen, Senior Director of Strategic Regulatory Solutions, IQVIA; Brian Healey, Global Head of Drug Development and Regulatory Strategy, IQVIA; and Claire Davies, Senior Director, Regulatory Affairs, IQVIA

As mid-size pharma companies work to stake their foothold across a competitive pharmaceutical landscape, teams must accommodate their challenges and empower their strengths. While mid-size companies are agile and amendable to innovation, they may lack the infrastructure and resources of larger companies. Failure to secure appropriate support can lead to compliance missteps, stalled assets, and the loss of valuable market opportunities. But with the right CRO partner, mid-size pharma can capitalize on their potential and ensure speed-to-market.

Though some may be cautious of the CRO route for fear of high costs, loss of control, or insufficient support, strategically selecting a partner will mitigate these concerns to transform challenges into opportunities. Download the full article to learn more about how a consultative, end-to-end CRO can supplement your team’s skillsets to help you achieve your targets; expand your global reach; and design a robust clinical, regulatory, and operational strategy.